Studies sodium in the skin of adults with atopic dermatitis
Observes skin sodium, diet and skin barrier in adults aged 50 and older with eczema.
Plain-language title generated from the registry record
Registry title: Sodium in the Skin and Atopic Dermatitis
Key facts
- Where
- San Francisco, United StatesSee the 2 sites
Where in United States
- San Francisco VA Medical CenterSan Francisco, United StatesTaking people
- UCSF Mt Zion CampusSan Francisco, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT06998446
- Record updated
- 14 July 2026
- Original description
The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above.Read full original descriptionShow less
Sodium in the Skin and Atopic Dermatitis
The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above.
The study is designed to test whether diet and skin barrier function are associated with skin sodium concentration and whether skin sodium concentration is linked to atopic dermatitis and immune profiles over time.
Participants will be asked to complete questionnaires, provide bio samples, and undergo non-contrast sodium MRI at 2-3 time points over 3-24 months.
Inclusion: Ages 50 years and above; Willing to undergo non-contrast MRI (e.g., no contraindications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips or pregnancy).
Exclusion: Currently receiving phototherapy or taking systemic medications for atopic dermatitis including cyclosporine, methotrexate, or other broad immunosuppressive medications; (Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the criteria for severe disease.); History of autoimmune disease; Cardiac events in the last six months; Current use of medications that influence sodium excretion (e.g. thiazide diuretics, SGLT2 inhibitors and spironolactone), and/or chemotherapy or antibiotic treatment; Impaired function of the liver or kidneys (glomerular filtration rate <60ml/min).